Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -7.21% | -59.41% | 331.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -7.21% | -59.41% | 331.52% |
| Cost of Revenue | -- | -- | 117.81% | 113.51% | 104.19% |
| Gross Profit | -- | -- | -45.46% | -98.10% | 690.66% |
| SG&A Expenses | -- | -- | -11.02% | -21.05% | -0.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -25.43% | -33.25% | -14.45% |
| Operating Income | -- | -- | 31.26% | 22.93% | 28.85% |
| Income Before Tax | -- | -- | 51.38% | 43.59% | 34.18% |
| Income Tax Expenses | -- | -- | 188.89% | -33.33% | -58.97% |
| Earnings from Continuing Operations | -- | -- | 51.32% | 43.58% | 34.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 41.80% | 47.66% | -30.17% |
| Net Income | -- | -- | 28.26% | 29.16% | 34.62% |
| EBIT | -- | -- | 31.26% | 22.93% | 28.85% |
| EBITDA | -- | -- | 25.62% | 14.14% | 31.63% |
| EPS Basic | -- | -- | 48.32% | 45.73% | 37.05% |
| Normalized Basic EPS | -- | -- | -- | -- | 45.84% |
| EPS Diluted | -- | -- | 48.32% | 45.73% | 37.05% |
| Normalized Diluted EPS | -- | -- | -- | -- | 45.84% |
| Average Basic Shares Outstanding | -- | -- | 25.81% | 21.83% | 5.17% |
| Average Diluted Shares Outstanding | -- | -- | 25.81% | 21.83% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |